Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $21.8400 (4.05%) ($20.5600 - $21.8900) on Fri. May. 22, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.89% (three month average) | RSI | 84 | Latest Price | $21.8400(4.05%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.6% a day on average for past five trading days. | Weekly Trend | TGTX advances 8.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(58%) ARKK(55%) IWO(55%) IBB(54%) | Factors Impacting TGTX price | TGTX will decline at least -4.445% in a week (0% probabilities). VIXM(-34%) VXX(-32%) UUP(-17%) DRIV(-2%) TBT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4.445% (StdDev 8.89%) | Hourly BBV | 0 () | Intraday Trend | 4.3% | | | |
|
5 Day Moving Average | $20.47(6.69%) | 10 Day Moving Average | $20.26(7.8%) | 20 Day Moving Average | $17.59(24.16%) | To recent high | 0% | To recent low | 205.9% | Market Cap | $2.766b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |